Efficacy and safety of concurrent chemoradiotherapy with or without Nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: Prospective comparative study - ESCORT-N study

BACKGROUND: Nimotuzumab is an anti-epidermal growth factor receptor monoclonal antibody which can be added to chemoradiotherapy (CRT) to improve efficacy for management of locally advanced squamous cell carcinoma of the head and neck (LASCCHN). We prospectively evaluated the efficacy and safety of n...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Ashok, Chakravarty, Nilotpal, Bhatnagar, Sharad, Chowdhary, G. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
ORIGINAL ARTICLE: Head and Neck Cancers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498712/
https://www.ncbi.nlm.nih.gov/pubmed/31069191
http://dx.doi.org/10.4103/sajc.sajc_38_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498712/
https://www.ncbi.nlm.nih.gov/pubmed/31069191
http://dx.doi.org/10.4103/sajc.sajc_38_18

Ejemplares similares